# Targeted & Novel Therapies — GCMD Library living collection

Updated: n/a · 5 episodes · 17 cited statements

## Episodes
### Kinase Inhibitors
- [A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric and Young Adult Solid Tumors](https://library.globalcastmd.com/article/a-phase-1-2-study-of-lenvatinib-in-combination-with-everolimus-in-recurrent-and-16982) — article · [machine version](https://library.globalcastmd.com/article/a-phase-1-2-study-of-lenvatinib-in-combination-with-everolimus-in-recurrent-and-16982.md)
- [Pediatric BRAF (V600E)-Mutated Pancreatic Acinar Cell Carcinoma With Complete and Durable Response to Dabrafenib and Trametinib](https://library.globalcastmd.com/article/pediatric-braf-mutated-pancreatic-acinar-cell-carcinoma-with-complete-and-durabl-16987) — article · [machine version](https://library.globalcastmd.com/article/pediatric-braf-mutated-pancreatic-acinar-cell-carcinoma-with-complete-and-durabl-16987.md)

### Immunotherapy
- [In vivo expansion and activation of γδ T cells as immunotherapy for refractory neuroblastoma: A phase 1 study.](https://library.globalcastmd.com/article/in-vivo-expansion-and-activation-of-t-cells-as-immunotherapy-for-refractory-neur-17034) — article · [machine version](https://library.globalcastmd.com/article/in-vivo-expansion-and-activation-of-t-cells-as-immunotherapy-for-refractory-neur-17034.md)
- [Severe cytokine release syndrome in a patient receiving PD-1-directed therapy.](https://library.globalcastmd.com/article/severe-cytokine-release-syndrome-in-a-patient-receiving-pd-1-directed-therapy-17028) — article · [machine version](https://library.globalcastmd.com/article/severe-cytokine-release-syndrome-in-a-patient-receiving-pd-1-directed-therapy-17028.md)
- [Herpes simplex virus oncolytic therapy for pediatric malignancies](https://library.globalcastmd.com/article/herpes-simplex-virus-oncolytic-therapy-for-pediatric-malignancies-16998) — article · [machine version](https://library.globalcastmd.com/article/herpes-simplex-virus-oncolytic-therapy-for-pediatric-malignancies-16998.md)

## Statements
Every statement is attributed, typed, and timestamped; the link is the citation.
- Patients aged 2-21 years with select recurrent or refractory solid tumors were eligible for enrollment. (recommendation) (no timestamp yet)
- Phase 2 enrollment was limited to patients with Ewing sarcoma, rhabdomyosarcoma, or high-grade glioma who had received no more than 2 prior VEGF/VEGFR-targeted therapies. (recommendation) (no timestamp yet)
- The recommended Phase 2 dose was lenvatinib 11 mg/m2 combined with everolimus 3 mg/m2 orally once daily. (recommendation) (no timestamp yet)
- Dose-limiting toxicities at the 11 mg/m2 lenvatinib dose level included proteinuria in one patient and hypertriglyceridemia with hypercholesterolemia in one patient, occurring in 2 of 12 patients treated. (research) (no timestamp yet)
- Two patients with rhabdomyosarcoma experienced partial response by Week 16. (research) (no timestamp yet)
- Two patients with Ewing sarcoma experienced prolonged disease control lasting at least 23 weeks. (research) (no timestamp yet)
- No objective responses were observed in patients with Ewing sarcoma or high-grade glioma by Week 16. (research) (no timestamp yet)
- The safety profile in pediatric and young adult patients was similar to that observed in adults with renal cell carcinoma treated with this combination. (research) (no timestamp yet)
- A subset of pediatric cancer patients have disease resistant to traditional therapies such as surgery, chemotherapy, and radiation. (established) (no timestamp yet)
- Patients with treatment-resistant pediatric cancers require newer, targeted treatments used alone or in combination with more traditional approaches. (recommendation) (no timestamp yet)
- Oncolytic herpes simplex virus (HSV) offers promise for several difficult to treat pediatric malignancies. (research) (no timestamp yet)
- Oncolytic HSV therapy has potential benefit in pediatric solid tumors including brain tumors, neuroblastomas, and sarcomas. (research) (no timestamp yet)
- Many challenges need to be addressed prior to moving oncolytic HSV therapy from the laboratory to the bedside in the pediatric population. (open) (no timestamp yet)
- Cytokine release syndrome is a phenomenon of immune hyperactivation described in the setting of cellular and bispecific T-cell engaging immunotherapy. (established) (no timestamp yet)
- Severe cytokine release syndrome can occur in patients receiving anti-PD-1 checkpoint blockade therapy. (research) (no timestamp yet)
- CD3+ γδ+ T cells comprise 2% to 5% of circulating T cells with Vγ9Vδ2+ cells the dominant circulating subtype. (established) (no timestamp yet)
- Vγ9Vδ2+ cells recognize non-peptide phosphoantigens and stress-associated NKG2D ligands expressed on malignant cells. (established) (no timestamp yet)

---
Educational content from recorded physician discussions — not medical advice. Cite the canonical URL or the ?t= deep link. Policy: https://library.globalcastmd.com/ai
